Drug Discovery@nature.com 23 September 2011

TABLE OF CONTENTS 23 September 2011 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Miami 2012 Winter Symposium: Nanotechnology in Biomedicine February 26-29, 2012 • Miami, FL, USA The 45th Miami Winter Symposium will bring together leaders in the field to discuss breakthroughs in new nanomaterials and the challenges in translating these materials into products for the clinic and laboratory. For more information and to register, visit: www.nature.com/natureconferences/miami/mws2012?WT.mc_id=NC1108TK010   News Top Clues emerge to explain first successful HIV vaccine trial doi:10.1038/news.2011.541 Immune responses of patients could point way forward for future vaccines. Full Text New models emerge for commercializing university assets doi:10.1038/nbt0911-774 Some universities are setting up their own seed and venture funds while others are collaborating directly with pharma and biotech companies to commercialize good research. Full Text Combination products neglected by FDA device evaluation doi:10.1038/nm0911-1024a Experts claim that the current process for reviewing combination products is flawed, with separate centers handling small-molecule drugs, biologics or devices lacking the broad expertise to effectively evaluate their safety and efficacy in combination. Full Text BIO marches to Congress with growth package in hand doi:10.1038/nbt0911-776 Members of the Biotechnology Industry Organization's board of directors have presented to Congress a long list of suggested ways to improve the environment for biotechs. Full Text Analysis Top New targets for HIV doi:10.1038/scibx.2011.1005 Researchers have revealed a suite of new targets for HIV-1, all of which belong to a purinergic signaling cascade that mediates steps between HIV binding and fusion with the host cell. Full Text Identifying R&D outliers doi:10.1038/nrd3555 Although the average ability of pharmaceutical R&D to create value has declined, there is in fact a large variation in R&D performance across the industry. This article presents an analysis identifying companies — termed 'outliers' — that seem to have been more successful in counteracting the overall industry trend of declining R&D productivity. Full Text Belatacept doi:10.1038/nrd3536 In June 2011, belatacept (Nulojix; Bristol-Myers Squibb), a fusion protein that inhibits T cell activation by binding to CD80 and CD86, was approved by the US FDA for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. Full Text Research Highlights Top Selective oxycution? doi:10.1038/nrd3543 A new study demonstrates that the natural product piperlongumine may have promising cancer-specific cytotoxicity. Full Text Rescuing age-related memory loss doi:10.1038/nrn3096 Arnsten and colleagues provide new insight into the physiological basis of age-related memory decline and a potential means to restore function. Full Text Vaccines: Structure-based design doi:10.1038/nrd3539 Vaccination with a chimeric antigen developed using a structure-based strategy provides broad protection against multiple variants of the pathogen that causes meningitis. Full Text Research & Reviews Top Targeting cancer metabolism: a therapeutic window opens doi:10.1038/nrd3504 Cancer cells have adapted metabolically to support their characteristic high rate of proliferation. This review discusses how the metabolic differences between cancer cells and normal cells could be therapeutically targeted. Full Text Minimum information about a bioactive entity (MIABE) doi:10.1038/nrd3503 This article proposes reporting guidelines for bioactive entities, developed by representatives from industry, academia and data resource providers, which could aid the analysis of data to provide insight for developing improved molecules. Full Text Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner doi:10.1038/nm.2378 Pajvani and colleagues report a new role of Notch in glucose metabolism, and suggest that Notch inhibition could be beneficial in diabetes. Full Text The transcription factor FOXM1 is a cellular target of the natural product thiostrepton doi:10.1038/nchem.1114 This paper shows that thiostrepton, which has anticancer properties, binds to FOXM1, preventing its interaction with several gene promoters. This illustrates the druggability of transcription factors, and provides a molecular basis for targeting FOXM1. Full Text Drug Discovery JOBS of the week 4 year Science Foundation Ireland-funded PhD Studentship (Ref: SMR11-03) Dundalk Institute of Technology Dundalk, IE Staff Scientist – Marine Carbon Dioxide Research National Environment Research Council Southampton, GB Postdoc in Biochemistry / Proteomics University of South Florida, College of Medicine Tampa, US Scientific Programmer - HGNC European Bioinformatics Institute (EBI) Cambridge, GB PhD Fellowships in Life Sciences university of lausanne Lausanne, CH More Science jobs from Drug Discovery EVENT 12th International Conference on Alzheimer's Drug Discovery 26-27.09.11 NJ, USA More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.